We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02054806
Recruitment Status : Completed
First Posted : February 4, 2014
Last Update Posted : May 13, 2021
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : April 30, 2021
Actual Study Completion Date : April 30, 2021
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 April 19, 2022
 January 20, 2023
2 February 6, 2023
 
Publications of Results:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):